title: Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
abstract: The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12% fall in total cholesterol and a 20% increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20%. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.
authors.affiliation: E. Grossi Paoletti Center, Institute of Pharmacological Sciences, University of Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Pazzucconi
authors.forename: L
authors.initials: L
authors.lastname: Mannucci
authors.forename: L
authors.initials: L
authors.lastname: Mussoni
authors.forename: G
authors.initials: G
authors.lastname: Gianfranceschi
authors.forename: P
authors.initials: P
authors.lastname: Maderna
authors.forename: P
authors.initials: P
authors.lastname: Werba
authors.forename: G
authors.initials: G
authors.lastname: Franceschini
authors.forename: C R
authors.initials: CR
authors.lastname: Sirtori
authors.forename: E
authors.initials: E
authors.lastname: Tremoli
mesh_terms: D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
chemical_list: D008055:Lipids; D008074:Lipoproteins; D010975:Platelet Aggregation Inhibitors; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator; D001629:Bezafibrate